Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

3 1 1 1

What is this study about?

This clinical trial focuses on people with Type 2 Diabetes who are overweight and currently using insulin. The study examines the effectiveness of combining two medications: semaglutide (Ozempic) and a reduced dose of insulin glargine (Lantus), compared to using a higher dose of insulin glargine alone.

The trial investigates whether using semaglutide along with a lower dose of insulin can control blood sugar levels just as effectively as using a higher dose of insulin by itself. Both medications are given through subcutaneous injection (under the skin) using pre-filled injection pens. The semaglutide is given once weekly, while insulin glargine is administered once daily.

The study lasts for 40 weeks and involves measuring changes in HbA1c (a measure of average blood sugar levels over the past 2-3 months). Participants will receive either a combination of semaglutide with reduced insulin glargine or insulin glargine alone. The study also looks at changes in body weight and how satisfied participants are with their treatment.

1 Initial treatment period

You will be assigned to one of two treatment groups. Both groups will receive insulin glargine (Lantus SoloStar) through under-skin injection.

If you’re in the first group, you will receive a reduced dose of insulin glargine along with semaglutide (Ozempic) 2 mg once weekly through under-skin injection.

If you’re in the second group, you will receive only insulin glargine at an adjusted dose through under-skin injection.

2 Treatment duration

The treatment period will last for 40 weeks.

During this time, you will need to continue taking your regular diabetes medication (metformin, with or without SGLT-2 inhibitors).

3 Measurements and monitoring

Your blood sugar control (HbA1c) will be measured at the start of the study and after 40 weeks.

Your body weight will be monitored throughout the study.

The amount of insulin you use daily will be tracked.

You will complete a questionnaire about your satisfaction with the diabetes treatment at week 40.

4 Study completion

The study is expected to end in July 2025.

At the end of the study, your blood sugar control, weight changes, and insulin use will be evaluated.

You will provide feedback about your treatment experience through a satisfaction questionnaire.

Who Can Join the Study?

  • Must be diagnosed with type 2 diabetes for at least 180 days before screening
  • Must have a HbA1c level (a measure of average blood sugar over the past 2-3 months) between 7% and 10% at screening
  • Must have a Body Mass Index (BMI) of 25 or higher at screening (BMI is a measure of body fat based on height and weight)
  • Must be taking stable doses of diabetes medications for at least 90 days before screening, including either:
    • Metformin at least 1500 mg daily or highest tolerated dose
    • Metformin combination medications at least 1500 mg daily or highest tolerated dose
  • Must be using a once-daily long-acting insulin at a dose of 40 units or less per day for at least 90 days before screening
  • Can be either male or female
  • Must be an adult (18 years or older)
  • Can be taking SGLT-2 inhibitors (a type of diabetes medication) along with other treatments
  • May have received short-term rapid-acting insulin treatment for up to 14 days before screening

Who Cannot Join the Study?

  • Known or suspected hypersensitivity to semaglutide or any of its components
  • History of diabetic ketoacidosis (a serious complication of diabetes where the body produces high levels of blood acids)
  • History of pancreatitis (inflammation of the pancreas)
  • Personal or family history of medullary thyroid carcinoma (a type of thyroid cancer)
  • Current treatment with other GLP-1 receptor agonists (diabetes medications similar to semaglutide)
  • Pregnancy or breastfeeding
  • Severe kidney or liver disease
  • History of gastroparesis (delayed stomach emptying)
  • Any serious medical condition that could interfere with study participation
  • Current participation in other clinical trials
  • History of alcohol or drug abuse within the past 12 months
  • Mental condition that could interfere with study compliance
  • Use of weight loss medications within 90 days before study entry
  • Major surgery planned during the study period

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Other Sites

Site Name City Country Status
Ospedale San Raffaele S.r.l. Milan Italy
Diabet2 s.r.o. Prague Czechia
Geniko Nosokomeio Peiraia Tzaneio Piraeus Greece
Lorad Gwyoyov Hxjoqhgf Of Aaavtr Athens Greece
Uryxrdpcrc Gglhnnu Hdehunfn Om Tbqhsyrlatoj Anejf Thessaloniki Greece
Awhoamzsf Hrgkwhgw Athens Greece
Ulqqqmzewd Gqdvncn Hizusgwj Os Aecqdcybgyzcea Alexandroupoli Greece
Iz Dqk spowfw Lučenec Slovakia
Azvnzyk Otbolypmajw Pmuz Gjofxcew Xytwy Bergamo Italy
Uytvpdygvc Dcmxd Sbwiv Dg Bhwifsc Brescia Italy
Stasye Dx Sybke Dg Ljj Iqhee Byljkat Palma Spain
Clqrzjf Moueubq Db Dttqmxpept Sd Tnjsfflxc Aznnihhsw Nteecc Syigpq Brasov Romania
Grvuvt Nmdwztrbev Tizazvkiazepi Gphamw Pjgqntbycxzm Thessaloniki Greece
Cauy Cwiykg Cijabwk Awwbhsrcu Bgufl Anucmsynfg Braga Portugal
Tolcrk Cdyjtn Ssny Thessaloniki Greece
Epuios sgukkx Nachod Czechia
Uyxfbemysw Gncddvw Hdcrrnxh Adokxqn Athens Greece
Caxusxbahm Spsqkr Iasi Romania
Spkbhmgo Jfzdqgcx dd Upohxsr Tzludynkxt Targoviste Romania
Paziisrqh Sdssijhel I Saskltb Sehq Barcelona Spain
Dodwhkduustfzg Sdvgxe Targu Mures Romania
Amaoazu Ucr Taqaiwl nlbs owwpt Leghorn Italy
Rzgvbtky swjrwd Prague Czechia
Ddptbjphtodkyphaatm Soeasj Bucharest Romania
Chgyxcb Mdmwhme Ssi Solrsk Syztiv Timisoara Romania
Nowpm Mysykmk Ctdxsfe Srlpkf Ploiesti Romania
Maigrbt Prmjbcih Sltpim Oradea Romania
Dcbbmfdmke spvelr Bojnice Slovakia
Btnzss sevrzk Sturovo Slovakia
Fclowfwqmd sxetq Nove Zamky Slovakia
Ddmvvy sniox s rpgp Poprad Slovakia
Dmfbwez somqwo Pardubice Czechia
Sepyiqut Ckxzxo Jpktktll Dh Uskcuxx Snkgkzs Aahchhw Abkoum Crzhcgylx Constanta Romania
Ceidyq Hblvwawltf Dj Bshrw Vnusz Ewobuk (hbzf Epeyinc Aveiro Portugal
Hjqjhroj Scxum Mwczw Dryik Mkiojahjoplr Perugia Italy
Uycwlecbaq Mljtb Gdeywvr On Csgscdgig Catanzaro Italy
Esuxwpggzz Gbvsofo Cuqyev Oa Tkahedqlxrzl Thessaloniki Greece
Cunypcg Kkryxl Sziwqc Satu Mare Romania
Hijldryr Ukhizrqhmlmdv Inbahtp Lbuhwj Madrid Spain
Odbjskid Sombg Mviht Gjrdfhg Lxatbk Latina Italy
Gdohkbui Siofkp Oradea Romania
Mxtuwgri seqeyd Bratislava Slovakia
Uhfpdek Lggqr Do Szvnn Du Asar Maukv Ebiwjp Ponte De Lima Portugal
Stpfmwvn Cphjbc Jhhiurhb Du Uxiznqo Shn Afybbud Akuzvw Gzazkd Galati Romania
Uhrrfxj Lqyjd Dx Sqldv Dx Mnprqwdkjj Eaciub Senhora Da Hora Portugal
Dqob seuzxz Roznava Slovakia
Myhenimjipbh svtlkx Petrzalka Slovakia
Mdnqs Jngdq Zezafwpk Dhjxyedqsmht A Ixssxrz ssojrz Plzen 2-Slovany Czechia
Msuvf Mytxmcf Pahgxhnwop sqntja Prague Czechia

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Czechia Czechia
Not recruiting
01.09.2022
Greece Greece
Not recruiting
01.09.2022
Italy Italy
Not recruiting
01.09.2022
Portugal Portugal
Not recruiting
01.09.2022
Romania Romania
Not recruiting
01.09.2022
Slovakia Slovakia
Not recruiting
01.09.2022
Spain Spain
Not recruiting
01.09.2022

Trial locations

Semaglutide is a medication used to treat type 2 diabetes and help with weight management. It’s taken as an injection under the skin once a week. This medication works by helping control blood sugar levels and can help reduce appetite and body weight.

Insulin glargine is a long-acting insulin that is injected under the skin. It works by helping to control blood sugar levels throughout the day and night. It’s designed to work slowly to provide day-long blood sugar control for people with diabetes.

Type 2 Diabetes (T2D) – A chronic metabolic disorder characterized by high blood sugar levels due to the body’s ineffective use of insulin or reduced insulin production. The condition typically develops gradually, often in adults, and is strongly associated with lifestyle factors and genetic predisposition. The body either becomes resistant to insulin or doesn’t produce enough insulin to maintain normal glucose levels. Over time, this leads to various metabolic changes and can affect how the body processes carbohydrates, fats, and proteins. The disease usually progresses slowly, and symptoms may include increased thirst, frequent urination, fatigue, and blurred vision.

Overweight – A condition where a person’s body weight is higher than what is considered healthy for their height, typically measured by body mass index (BMI) between 25 and 29.9. It occurs when the body accumulates excess fat due to an imbalance between calorie intake and energy expenditure. The condition can develop gradually over time and is influenced by various factors including diet, physical activity levels, genetics, and metabolism. This condition often coexists with other metabolic disorders and can affect overall health status.

Trial ID:
2024-510612-75-00
Protocol code:
NN9535-4801
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

    Recruiting

    3 1
    Investigated Drugs:
    Czechia Germany Poland Slovakia Spain
  • Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Bulgaria Denmark France Greece The Netherlands +3